Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

Because most patients with advanced non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients treated with radiolabeled Lym‐1.

[1]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[2]  G. Denardo,et al.  Radioimmunotherapy of lymphoma: a UC Davis experience. , 1995, Hybridoma.

[3]  G. Denardo,et al.  Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.

[4]  K. Lamborn,et al.  Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. , 1994, Cancer research.

[5]  G. Denardo,et al.  Effect of lym‐1 radioimmunoconjugate on refractory chronic lymphocytic leukemia , 1994, Cancer.

[6]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[7]  M. Czuczman,et al.  Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Kaminski,et al.  Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.

[9]  R. Meredith,et al.  Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma , 1993 .

[10]  A. M. Zimmer,et al.  A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. , 1993, Cancer biotherapy.

[11]  D. Goldenberg,et al.  Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Winter,et al.  Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. , 1987, Cancer research.

[13]  J. McGahan,et al.  Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies , 1987, The International journal of biological markers.

[14]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Denardo,et al.  Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[16]  M. Buyse,et al.  Cancer Clinical Trials: Methods and Practice. , 1985 .

[17]  M. Shapiro,et al.  Reporting results from chemotherapy trials. Does response make a difference in patient survival? , 1984, JAMA.

[18]  J. Hokanson,et al.  Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. , 1983, Controlled clinical trials.